The United States market has seen a robust performance recently, climbing 1.8% in the last 7 days and up 28% over the past year, with earnings forecasted to grow by 17% annually. For investors seeking opportunities beyond well-known large-cap stocks, penny stocks—despite their somewhat outdated label—can still present compelling value propositions. These smaller or newer companies often offer growth potential at lower price points, especially when backed by strong financials and solid fundamentals.

Let's uncover some gems from our specialized screener.

Data I/O (DAIO)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Data I/O Corporation designs, manufactures, and sells programming and security deployment systems for electronic device manufacturers across the United States, Germany, China, Mexico, and Korea with a market cap of $29.97 million.

Operations: No specific revenue segments are reported for this company.

Market Cap: $29.97M

Data I/O Corporation, with a market cap of US$29.97 million, is navigating challenges typical for penny stocks. Despite being debt-free and having sufficient cash runway for over a year, the company remains unprofitable with increasing losses over the past five years. Recent earnings guidance suggests potential revenue growth in Q2 2026 to US$5-5.4 million, following a significant drop in Q1 sales to US$3.25 million from US$6.18 million the previous year. The company's strategic shift towards Programming-as-a-Service (PaaS) aims to create new revenue streams and enhance customer engagement amidst its volatile share price environment and recent private placement initiatives totaling $9 million.

Filana Therapeutics (FLNA)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Filana Therapeutics, Inc. is a clinical stage biotechnology company focused on developing drugs for neurodegenerative diseases, with a market cap of $72.46 million.

Operations: Filana Therapeutics does not report any segmented revenue data.

Market Cap: $72.46M

Filana Therapeutics, with a market cap of US$72.46 million, is navigating the complexities typical of pre-revenue biotech penny stocks. Despite being debt-free and having sufficient cash runway for over two years, it remains unprofitable with increasing losses over the past five years. Recent developments include promising preclinical data on simufilam for TSC-related epilepsy, which may bolster its research prospects despite ongoing regulatory challenges. The company's management team is relatively new, averaging 1.6 years in tenure, while its board members have more experience at 4.9 years on average. Filana recently rebranded from Cassava Sciences and changed its ticker to FLNA.

Castellum (CTM)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Castellum, Inc., along with its subsidiaries, operates as a technology company both in the United States and internationally, with a market cap of $76.63 million.

Operations: Revenue Segments: No revenue segments have been reported.

Market Cap: $76.63M

Castellum, Inc., with a market cap of US$76.63 million, reported first-quarter sales of US$14.29 million, up from the previous year. Despite being unprofitable and not expected to achieve profitability in the next three years, it has reduced its net loss significantly over time and boasts a strong balance sheet with short-term assets exceeding liabilities. The company is debt-free and maintains a cash runway for over three years based on current free cash flow trends. However, insider selling has been significant recently, and management's average tenure is relatively short at 1.8 years.

Make It Happen

• Investigate our full lineup of 331 US Penny Stocks right here.
• Looking For Alternative Opportunities? The latest GPUs need a type of rare earth metal called Neodymium and there are only 29 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.